Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Ocuphire Pharma
Farmington Hills, Michigan, United Statesocuphire.com ↗
- Ownership
- Public · OCUP
- Development stage
- Other
01
Overview
Ocuphire has FDA-approved RYZUMVI™ (phentolamine ophthalmic solution 0.75%) for treating pharmacologically induced mydriasis. The company has multiple Phase 3 trials ongoing for presbyopia and night vision disturbances, with data readouts expected in Q1 2025. Following acquisition of Opus Genetics, the company also has gene therapy candidates for inherited retinal diseases in Phase 1/2 trials.
- Therapeutic areas
- Ophthalmology
- Modalities
- Small moleculesGene therapy
- Industry
- Biotech
02
Partnerships
Viatris, Inc.Foundation Fighting Blindness
Beyond the preview
Go deeper on Ocuphire Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ocuphire Pharma.